Provectus Biopharma (PVCT) Announces Presentation of PV-10 Phase 1 Data in Chemoablation of HCC
Tweet Send to a Friend
Provectus Biopharma (NYSE: PVCT) announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
